Genomes and Genes
Summary: ERYTHROPOIETIN prepared by recombinant DNA technology.
Publications251 found, 100 shown here
- Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelingLaura Calvillo
Mario Negri Institute of Pharmacological Research, 20157 Milan, Italy
Proc Natl Acad Sci U S A 100:4802-6. 2003....
- Breast cancer trial with erythropoietin terminated unexpectedlyBrian Leyland-Jones
McGill University, Montreal, Canada
Lancet Oncol 4:459-60. 2003
- Plant recombinant erythropoietin attenuates inflammatory kidney cell injuryAndrew J Conley
Department of Biology, University of Western Ontario, London, ON, Canada, N6A 5B7
Plant Biotechnol J 7:183-99. 2009..These findings demonstrate that tobacco plants may be an attractive alternative for the production of large amounts of biologically active EPO...
- Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patientsI C MacDougall
Department of Renal Medicine, King s College Hospital, London, United Kingdom
J Am Soc Nephrol 10:2392-5. 1999..The longer half-life of NESP is likely to confer a clinical advantage over Epoetin by allowing less frequent dosing in patients treated for anemia...
- Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsJulia Bohlius
Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
Lancet 373:1532-42. 2009..We therefore did a meta-analysis of randomised controlled trials in which these drugs plus red blood cell transfusions were compared with transfusion alone for prophylaxis or treatment of anaemia in patients with cancer...
- Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialMichael Henke
Abteilung Strahlenheilkunde der Radiologischen Universitätsklinik, Hugstetter Strasse 55, D 79106, Freiburg, Germany
Lancet 362:1255-60. 2003..We investigated whether anaemia correction with epoetin beta could improve outcome of curative radiotherapy among patients with head and neck cancer...
- Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failureD W Johnson
Department of Renal Medicine, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia
Kidney Int 69:1806-13. 2006Administration of human recombinant erythropoietin (EPO) at time of acute ischemic renal injury (IRI) inhibits apoptosis, enhances tubular epithelial regeneration, and promotes renal functional recovery...
- Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in ratsMasanori Iwai
Department of Neurology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15261, USA
Stroke 38:2795-803. 2007..The current study investigates the effects of exogenous administration of EPO on revascularization and neurogenesis, 2 major events thought to contribute to neuronal replacement, in the neonatal brain after hypoxia/ischemia (H/I)...
- Recombinant erythropoietin in clinical practiceT Ng
Phase One Clinical Trials Unit Ltd, Plymouth, UK
Postgrad Med J 79:367-76. 2003..Besides highlighting both the historical and functional aspects of RHuEPO, this review discusses the applications of RHuEPO in clinical practice and the potential problems of RHuEPO treatment...
- Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysisArintaya Phrommintikul
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia
Lancet 369:381-8. 2007..Our aim was to determine whether targeting different haemoglobin concentrations with such treatment is associated with altered all-cause mortality and cardiovascular events in patients with anaemia caused by chronic kidney disease...
- Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampusSandra E Juul
Department of Pediatrics, University of Washington, Seattle, Washington 98195, USA
Pediatr Res 65:485-92. 2009....
- Pure red-cell aplasia and epoetin therapyCharles L Bennett
MidWest Center for Health Services Research and Policy Studies, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60611, USA
N Engl J Med 351:1403-8. 2004....
- Normalization of hemoglobin level in patients with chronic kidney disease and anemiaTilman B Drueke
Inserm Unité 507 and Assistance Publique Hôpitaux de Paris, Necker Hospital, Division of Nephrology, Paris, France
N Engl J Med 355:2071-84. 2006..Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established...
- Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasiaNorifumi Urao
Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto 602 8566, Japan
Circ Res 98:1405-13. 2006..In conclusion, Epo treatment inhibits the neointimal hyperplasia after arterial injury in an NO-dependent manner by acting on the injured vessels and mobilizing EPCs to the neo-endothelium...
- Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietinNicole Casadevall
Department of Hematology, Hotel Dieu, Paris, France
N Engl J Med 346:469-75. 2002..We investigated whether there was an immunologic basis for the anemia in these patients...
- Revised European best practice guidelines for the management of anaemia in patients with chronic renal failureFrancesco Locatelli
Nephrol Dial Transplant 19:ii1-47. 2004
- Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietinTed Wun
Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California 95817, USA
Cancer 98:1514-20. 2003..The authors performed a retrospective analysis to determine whether there was an increased rate of symptomatic venous thrombosis associated with the use of rHuEpo in patients with carcinoma of the uterine cervix and vagina...
- Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacityJ J Thomsen
Copenhagen Muscle Research Centre, Rigshospitalet, Section 7652, 2100, Copenhagen Ø, Denmark
Eur J Appl Physiol 101:481-6. 2007..8% as compared to pre rHuEpo administration. In conclusion, in healthy non-athlete subjects rHuEpo administration prolongs submaximal exercise performance by about 54% independently of the approximately 12% increase in VO2max...
- Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exerciseGabrielle Russell
Department of Physiology, Australian Institute of Sport, Canberra, Australia
Eur J Appl Physiol 86:442-9. 2002The aim of this study was to characterise the effect of prolonged low doses of recombinant erythropoietin (r-HuEPO) on the responses to submaximal and maximal exercise...
- Iron therapy in the pediatric hemodialysis populationBradley A Warady
Section of Pediatric Nephrology, Children s Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA
Pediatr Nephrol 19:655-61. 2004..In summary, although both oral and i.v. iron maintained patients in an iron-replete state in this short-term study, only i.v. therapy allowed for a significant improvement in iron stores...
- Characterization of the pharmacokinetics of human recombinant erythropoietin in blood and brain when administered immediately after lateral fluid percussion brain injury and its pharmacodynamic effects on IL-1beta and MIP-2 in ratsThomas Lieutaud
Department Reanimation et Anesthesiologie, Hopital Neurologique, Hospices Civils de Lyon, Lyon, France
J Neurotrauma 25:1179-85. 2008..Further, it has biological efficacy at 8 h on several inflammatory proteins, yet must be employed at high doses to cross the BBB...
- Neurorestorative treatment of stroke: cell and pharmacological approachesJieli Chen
Department of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan, USA
NeuroRx 3:466-73. 2006..Both the MSCs and the pharmacologic agents potentiate brain plasticity and neurobehavioral recovery after stroke...
- Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failureYiwen Li
Second Department of Internal Medicine, Gifu University School of Medicine, 1 1 Yanagido, Gifu 501 1194, Japan
Cardiovasc Res 71:684-94. 2006..We investigated the mechanisms, including the downstream signaling pathways, for the beneficial effect of late treatment with EPO on chronic post-MI heart failure...
- Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenograftsSophie Pinel
Laboratoire de Recherche en Oncologie, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
Int J Radiat Oncol Biol Phys 59:250-9. 2004..Furthermore, the consequences of rHuEPO administration on tumor response to fractionated radiotherapy (RT) were evaluated...
- Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft modelsJozsef Tovari
Department of Tumor Progression and Central Laboratory, National Institute of Oncology, Budapest, Hungary
Cancer Res 65:7186-93. 2005....
- Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobinKimberly L Blackwell
Division of Medical Oncology, Department of Medicine, Duke University Comprehensive Cancer Center, Erwin Road, Durham, NC 27710, USA
Cancer Res 63:6162-5. 2003..These data confirm that tumor oxygenation in nonanemic individuals may be improved through the administration of EPO, and this improvement appears to be independent of HgB effects...
- Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysisJulia Bohlius
Department of Internal Medicine I, University of Cologne, Cologne, Germany
J Natl Cancer Inst 97:489-98. 2005..Anemia associated with cancer and cancer therapy is an important clinical and economic factor in the treatment of malignant diseases...
- Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cellsCristobal Belda-Iniesta
Translational Oncology Unit CSIC UAM, Medical Oncology Division, Hospital Universitario La Paz, Universidad Autonoma de Madrid, Madrid, Spain
Cancer Biol Ther 6:1600-5. 2007Human recombinant erythropoietin (hrEPO) therapy might be associated with tumor progression and death. This effect has been suggested to be secondary to rhEPO binding to its receptor (EPOR) expressed on cancer cells...
- Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methodsDiego F Ossa
Oxford Outcomes Ltd, Oxford, UK
Pharmacoeconomics 25:223-37. 2007....
- Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemiaKeyvan Karkouti
Toronto General Hospital, University Health Network, Department of Anesthesia, 3 Eaton North, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
Can J Anaesth 53:11-9. 2006To determine if early recovery from severe post-operative anemia is accelerated by iv iron therapy alone or in combination with recombinant erythropoietin (EPO).
- An approach to using recombinant erythropoietin for neuroprotection in very preterm infantsJean Claude Fauchere
Clinic of Neonatology, University Hospital Zurich, Zurich, Switzerland
Pediatrics 122:375-82. 2008..We investigated whether administration of high-dose recombinant human erythropoietin to very preterm infants shortly after birth and subsequently during the first 2 days is safe in terms of short-term outcome...
- A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal ratsBrian A Kellert
Department of Pediatrics, University of Washington, Seattle, Washington 98195, USA
Pediatr Res 61:451-5. 2007..rEpo provides dose-dependent neuroprotection. Of the regimens tested, three doses of 5,000 U/kg was optimal because it provided maximal benefit with limited total exposure...
- Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volumeCarsten Lundby
Copenhagen Muscle Research Center, Rigshospitalet section 7652, 2100 Copenhagen, Denmark
J Physiol 578:309-14. 2007..9 and 53.9% during the study period, this mechanism seems as important for increasing arterial oxygen content as the well-known erythropoietic effect of Epo...
- Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucomaJames C Tsai
Brown Glaucoma Research Laboratory, Department of Ophthalmology, Columbia University College of Physicians and Surgeons, New York, USA
Curr Eye Res 30:1025-31. 2005..The aim of this pilot study was to evaluate the potential neuroprotective effect of an intravitreal injection of erythropoietin (EPO) on retinal ganglion cell (RGC) preservation in an episcleral vessel cautery-induced rat model of glaucoma...
- Anemia, tumor hypoxemia, and the cancer patientJohn Varlotto
Department of Radiation Oncology, Boston VA Medical Center, Boston, MA 02130, USA
Int J Radiat Oncol Biol Phys 63:25-36. 2005..To review the impact of anemia/tumor hypoxemia on the quality of life and survival in cancer patients, and to assess the problems associated with the correction of this difficulty...
- Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemiaCharles L Bennett
VA Chicago Healthcare System, Department of Medicine, Northwestern University Feinberg School of Medicine, and Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
JAMA 299:914-24. 2008..Although systematic overviews of trials have identified venous thromboembolism (VTE) risks, none have identified mortality risks with ESAs...
- Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the ratBruno Sepodes
Faculty of Pharmacy, Unit of Pharmacology and Pharmacotoxicology, University of Lisbon, Av Forcas Armadas, Lisbon, Portugal
Transpl Int 19:919-26. 2006..Using a rat model of liver I/R injury, we aimed to determine the effect of the administration of human recombinant erythropoietin (rhEPO) on liver injury. Rats were subjected to 30 min of liver ischemia followed by 2 h of reperfusion...
- Erythropoietin is a multifunctional tissue-protective cytokineSerhat Erbayraktar
The Kenneth S Warren Institute, 712 Kitchawan Road, Kitchawan, NY 10562, USA
Curr Hematol Rep 2:465-70. 2003..We review the evidence that EPO and its receptor function as a paracrine/autocrine system to mediate the protection of tissues subjected to metabolic stress...
- Blood pressure response to erythropoietin injection in hemodialysis and predialysis patientsKazuhisa Miyashita
Division of Nephrology, the Japanese Red Cross Medical Center, Tokyo, Japan
Hypertens Res 27:79-84. 2004..In conclusion, a single injection of rHuEPO increased blood pressure with a positive correlation with endothelin-1 release in hemodialysis patients, but not in predialysis chronic renal failure patients...
- Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migrationLei Wang
Department of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan 48202, USA
J Neurosci 26:5996-6003. 2006..These data demonstrate that activated endothelial cells can promote neural progenitor cell migration, and provide insight into the molecular mechanisms underlying the attraction of newly generated neurons to injured areas in brain...
- Erythropoietin regulates endothelial progenitor cellsFerdinand H Bahlmann
Department of Internal Medicine, Hannover Medical School, Carl Neuberg Strasse 1, 30625, Hannover, Germany
Blood 103:921-6. 2004..Erythropoietin increases the number of functionally active EPCs in humans. Administration of rhEPO or EPO analogs may open new therapeutic strategies in regenerative cardiovascular medicine...
- Do erythropoietin receptors on cancer cells explain unexpected clinical findings?Michael Henke
Klinik fur Strahlenheilkunde, Universitatsklinikum, Robert Koch Strasse, 3 D 79106, Freiburg, Germany
J Clin Oncol 24:4708-13. 2006..Recent reports suggest that cancer control may worsen if erythropoietin is administered. We investigated whether erythropoietin receptor expression on cancer cells may correlate with this unexpected finding...
- Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritisJ P Kaltwasser
Medizinische Klinik III, Bereich Rheumatologie, J W Goethe Universitat, Frankfurt Main, Germany
J Rheumatol 28:2430-6. 2001..v.) iron influences health related quality of life (HRQoL) and clinical outcome including disease activity...
- Erythropoietin crosses the blood-brain barrier to protect against experimental brain injuryM L Brines
The Kenneth S Warren Laboratories, 765 Old Saw Mill River Road, Tarrytown, NY 10591, USA
Proc Natl Acad Sci U S A 97:10526-31. 2000..Given r-Hu-EPO's excellent safety profile, clinical trials evaluating systemically administered r-Hu-EPO as a general neuroprotective treatment are warranted...
- Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivityMatthew E Hardee
Department of Pathology, Duke University Medical Center, Box 3893, Durham, NC 27710, USA
Mol Cancer Ther 5:356-61. 2006..Clinically, recombinant erythropoietin treatment of malignancy-related anemia has yet to be definitively associated with any modulation of ..
- Effects of recombinant erythropoietin on breast cancer-initiating cellsTiffany M Phillips
Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, 10833 LeConte Ave, Los Angeles, CA 90095 1714, USA
Neoplasia 9:1122-9. 2007..Cancer recurrence is thought to rely on the proliferation of cancer initiating cells (CICs). In breast cancer, CICs can be identified by phenotypic markers and their fate is controlled by the Notch pathway...
- Epo protects SOD2-deficient mouse astrocytes from damage by oxidative stressJing Liu
Department of Neurosurgery, Program in Neurosciences, Stanford University School of Medicine, California, USA
Glia 53:360-5. 2006..Our study demonstrates an important role for Epo in the protection of astrocytes from reactive oxygen species. We suggest that Epo can compensate in part for the antioxidant properties of mitochondrial SOD2 deficiency...
- MRI identification of white matter reorganization enhanced by erythropoietin treatment in a rat model of focal ischemiaLian Li
Department of Neurology, Henry Ford Hospital, Detroit, Mich 48202, USA
Stroke 40:936-41. 2009....
- Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexedCamilla Palumbo
Department of Experimental Medicine and Biochemical Sciences, Universita degli Studi di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Cancer Chemother Pharmacol 61:893-901. 2008..Human recombinant erythropoietin (rHuEpo) is currently used for the treatment of anemia in cancer patients...
- Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemiaO Thews
Institute of Physiology and Pathophysiology, Johannes Gutenberg University, Mainz, Germany
Br J Cancer 78:752-6. 1998..These data suggest that the correction of chemotherapy-induced anaemia by rhEPO (epoetin beta) treatment increases tumour radiosensitivity, presumably as a result of an improved oxygen supply to tumour tissue...
- Development and characterization of novel erythropoiesis stimulating protein (NESP)J C Egrie
Amgen Inc, One Amgen Center Drive, MS 27 4 A, Thousand Oaks, CA 91320 1799, USA
Br J Cancer 84:3-10. 2001..NESP is currently being evaluated in human clinical trials for treatment of anaemia and reduction in its incidence...
- Novel applications of recombinant erythropoietinEdward J Sharples
Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK
Curr Opin Pharmacol 6:184-9. 2006b>Recombinant erythropoietin (EPO) was introduced into clinical practice after the identification of EPO as the major haemopoietic growth factor determining survival and maturation of erythroid precursors...
- Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromesDario Ferrero
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista di Torino, Torino, Italy
Br J Haematol 144:342-9. 2009The efficacy of human recombinant erythropoietin (rEPO) in myelodysplastic syndromes (MDS) has generally been best in untransfused patients with 'refractory anaemia' according to the World Health Organization (WHO)...
- Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flapsMichele Buemi
Department of Internal Medicine, University of Messina, Italy
Acta Derm Venereol 82:411-7. 2002....
- Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patientsAbelardo Aguilera
Servicio de Nefrologia, Hospitales Universitarios de la Princesa y la Paz, Madrid, Spain
Adv Perit Dial 18:200-5. 2002..By decreasing leptin, rHuEPO could increase food intake and improve the nutritional status of PD patients. At baseline, we confirm the existence of a chronic inflammatory process in uremia...
- Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infantsSeyedeh Fatemeh Khatami
Tehran University of Medical Sciences, Tehran, Iran
Indian J Pediatr 75:1227-30. 2008Early recombinant erythropoietin therapy and iron therapy would decrease the need for red blood cells transfusions and prevents anemia of prematurity.
- Effect of rhEPO administration on serum levels of sTfR and cycling performanceK I Birkeland
Hormone Laboratory, Aker University Hospital and Norwegian University of Sport and Physical Education, Oslo
Med Sci Sports Exerc 32:1238-43. 2000We assessed the possibility of using soluble transferrin receptor (sTfR) as an indicator of doping with recombinant erythropoietin (rhEPO).
- Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trialH Donato
Clinical Research Area, Bio Sidus S A Laboratory, Buenos Aires, Argentina
Pediatrics 105:1066-72. 2000..We investigated whether early use of rHuEPO would reduce the total transfusion requirement and/or the number of transfusions throughout the first 2 weeks of life...
- Derivatives of erythropoietin that are tissue protective but not erythropoieticMarcel Leist
H Lundbeck A S, 2500 Valby, Denmark
Science 305:239-42. 2004....
- Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesisM E Hardee
Department of Pathology, Duke University Medical Center, Box 3893, Durham, NC 27710, USA
Br J Cancer 93:1350-5. 2005..Improved tumour oxygenation should translate into increased treatment response. Exogenous recombinant erythropoietin (rEpo) has been recently shown to increase tumour oxygenation in a mammary carcinoma model...
- The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infantsGulcan Turker
Division of Neonatology, Department of Pediatrics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
Am J Perinatol 22:449-55. 2005..We suggest that r-Hu EPO combined with early enteral iron is both effective and safe in infants<1000 g...
- Pure red-cell aplasia and recombinant erythropoietinSharon K Gershon
N Engl J Med 346:1584-6; author reply 1584-6. 2002
- Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cellsLaurie Feldman
Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Prostate 66:135-45. 2006..EpoR have been identified on a variety of non-hematopoietic cells, both normal and malignant, however, little is known about the function of EpoR on malignant cells...
- Time and temperature dependant changes in red blood cell analytes used for testing recombinant erythropoietin abuse in sportsNeil Robinson
Laboratoire Suisse d Analyse du Dopage, Institut Universitaire de Medecine Legale, Lausanne, Switzerland
Clin Lab 50:317-23. 2004..the effect of temperature on the possible deterioration of red blood cell analytes used for testing recombinant erythropoietin abuse...
- Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shockF Squadrito
Institute of Pharmacology, School of Medicine, University of Messina, Italy
Br J Pharmacol 127:482-8. 1999..Finally rh-EPO inhibited the activity of iNOS in peritoneal macrophages activated with endotoxin. 4. Our data suggest that rh-EPO protects against SAO shock by inhibiting iNOS activity...
- Enhanced sialylation of recombinant erythropoietin in CHO cells by human glycosyltransferase expressionYeon Tae Jeong
Department of Biological Sciences, KAIST, Daejeon 305 701, Korea
J Microbiol Biotechnol 18:1945-52. 2008..Thus, coexpression of alpha2,3-ST and beta1,4-GT may be beneficial for producing therapeutic glycoproteins with enhanced sialylation in CHO cells...
- Effect of administering recombinant erythropoietin to women with postpartum anemia: a meta-analysisAnne C Kotto-Kome
Division of Neonatology, Department of Pediatrics, University of South Florida College of Medicine, All Children s Hospital, St Petersburg, FL 33772, USA
J Perinatol 24:11-5. 2004b>Recombinant erythropoietin (rEpo) has been administered to women with postpartum anemia in an attempt to accelerate their increase in hemoglobin concentration and reduce postpartum transfusions...
- Erythropoietin protects against necrotizing enterocolitis of newborn rats by the inhibiting nitric oxide formationAbdullah Kumral
Department of Pediatrics, School of Medicine, Dokuz Eylul University, Izmir, Turkey
Biol Neonate 84:325-9. 2003..The aim of this study was to investigate NO formation in an experimental model of NEC and the possible role of NO in the protection Epo provides against NEC...
- Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietinTodd M Blodgett
Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Clin Nucl Med 29:161-3. 2004..This case demonstrates the need to consider erythropoietin in the differential diagnosis of possible etiologies causing diffuse bone marrow uptake on PET scans...
- Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromesPellegrino Musto
Unit of Haematology and Stem Cell Transplantation, IRCCS Casa Sollievo della Sofferenza, S Giovanni Rotondo, Italy
Br J Haematol 122:269-71. 2003Thirteen patients with low-to-intermediate risk myelodysplastic syndrome (MDS) received recombinant erythropoietin (r-EPO) at the single, weekly dose of 40.000 U for at least 8 weeks. Five patients (38...
- Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical traumaElisabeth Kjellen
Departments of Oncology, Lund University Hospital, Lund
Acta Otolaryngol 126:545-7. 2006..It could be hypothesized that the effects of rHuEpo on tumour cell growth might only be manifested in vivo and after cell trauma, and that treating anaemia with rHuEpo might contribute to poor outcome after incomplete surgical resection...
- Impact of very early high doses of recombinant erythropoietin on anemia and allograft function in de novo kidney-transplant patientsNassim Kamar
Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France
Transpl Int 23:277-84. 2010..High doses of ESA within the first month of kidney transplantation have no impact on anemia or renal function by 1 month post-transplant...
- Kinetic and thermodynamic analysis of thermal unfolding of recombinant erythropoietinT Arakawa
Alliance Protein Laboratories, Thousand Oaks, CA 91360, USA
Biosci Biotechnol Biochem 65:1321-7. 2001..0, the results are similar, i.e., EPO suffered a substantial aggregation, while it showed little aggregation in 20 mm Tris or histidine at pH 7.0 and 20 mm glycine at pH 6.3 under identical heat treatment...
- Recombinant erythropoietin and blood transfusion in selected preterm infantsM P Meyer
Neonatal Unit, Kidz First, Middlemore Hospital and the University of Auckland, New Zealand
Arch Dis Child Fetal Neonatal Ed 88:F41-5. 2003To comprehensively identify preterm infants likely to require blood transfusion and to investigate the effectiveness of recombinant erythropoietin in this high risk subgroup.
- Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude miceGeorg Stüben
Department of Radiotherapy, West German Tumor Centre, Universitatsklinikum, Essen, Germany
Int J Radiat Oncol Biol Phys 55:1358-62. 2003..The effect of recombinant human erythropoietin (rhEPO) on the radiosensitivity of human tumor xenografts growing in anemic and nonanemic nude mice was studied...
- Managing the anemia of prematurity: red blood cell transfusions versus recombinant erythropoietinR G Strauss
University of Iowa College of Medicine, Iowa City, Iowa 52242-1182, USA
Transfus Med Rev 15:213-23. 2001..b>Recombinant erythropoietin therapy has not been widely adopted because it does not consistently reduce the need for red blood cell ..
- Effects of human recombinant erythropoietin on differentiation and distribution of erythroid progenitor cells on murine medullary and splenic erythropoiesis during hypoxia and post-hypoxiaS M Mide
Department of Physiology, University of Buenos Aires, School of Dentistry, Buenos Aires, Argentina
In Vivo 15:125-32. 2001..It is noteworthy that our studies show that the spleen functions as a large reservoir of erythroid precursors for hypoxia-induced stress erythropoiesis...
- Erythropoietin biology in cancerMatthew E Hardee
Department of Pathology, Duke University Medical Center, Durham, NC 22710, USA
Clin Cancer Res 12:332-9. 2006..This review describes Epo and EpoR biology, focusing on the pleiotropic effects of Epo on nonhematopoietic tissues as well as the expression and function of EpoR in cancer cells...
- Isolation and characterization of an anti-recombinant erythropoietin single-chain antibody fragment using a phage display antibody libraryJiebo Mi
Institute of Analytical Chemistry, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, P R China
Anal Bioanal Chem 383:218-23. 2005..The reported method is a very powerful tool to produce specific antibodies for rHuEPO detection demands...
- Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patientsE Movilli
Division and Chair of Nephrology, Spedali Civili and University of Brescia, Italy
Nephrol Dial Transplant 16:111-4. 2001..By optimizing rHuEpo responsiveness, an adequate dialysis treatment can contribute to the reduction of the costs of rHuEpo therapy...
- Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitroMauro Vairano
Institute of Pharmacology, Catholic University Medical School, Rome, Italy
Eur J Neurosci 16:584-92. 2002....
- Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietinSandra E Juul
Department of Pediatrics, University of Washington, Seattle, Wash 98195, USA
Biol Neonate 85:138-44. 2004..We demonstrate that high-dose rEpo was well tolerated and results in neuroprotective concentrations in spinal fluid of adult and developing animal models by 2-2.5 h after injection...
- Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patientsAantje V Kharagjitsingh
Department of Internal Medicine, Medical Center Haaglanden, Westeinde, Den Haag, The Netherlands
Kidney Int 68:1215-22. 2005..The objectives of this study were to determine the incidence and causes of recombinant EPO hyporesponse, of antibodies to EPO in patients on dialysis, and to relate the detection of anti-EPO antibodies to the presence of PRCA...
- Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatinAlexandre I Belenkov
Department of Oncology, Division of Radiation Oncology, Montreal General Hospital, Montreal, Quebec, Canada
Mol Cancer Ther 3:1525-32. 2004..Our findings indicate that rhEPO result in a significant, JAK2-dependent, in vitro resistance to ionizing radiation and to cisplatin in the human cancer cells lines studied in this report...
- Recombinant erythropoietin is neuroprotective in a novel mouse oxidative injury modelSandra E Juul
Department of Pediatrics, University of Washington, Seattle, WA 98195 6320, USA
Dev Neurosci 30:231-42. 2008..we developed a neonatal mouse model of moderate to severe oxidative brain injury and hypothesized that recombinant erythropoietin (rEpo) would decrease the expression of proapoptotic and proinflammatory genes 24 and 48 h, respectively,..
- The importance of anemia and its correction in the management of severe congestive heart failureDonald S Silverberg
Department of Nephrology, Tel Aviv Medical Center, Weizman 6, Tel Aviv 64239, Israel
Eur J Heart Fail 4:681-6. 2002..This so-called Cardio Renal Anemia Syndrome is very common in CHF. Its successful treatment demands close cooperation between cardiologists and nephrologists...
- Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression modelKevin K Suk
Loma Linda University, School of Medicine, Loma Linda, California 92354, USA
J AAPOS 12:233-8. 2008..We sought to determine whether rhEPO is an independent risk factor for the development of ROP...
- Enhanced sialylation of recombinant erythropoietin in genetically engineered Chinese-hamster ovary cellsYeon Tae Jeong
Department of Biological Sciences, KAIST Korea Advanced Institute of Science and Technology, 335 Gwahangno, Yuseong Gu, Daejeon 305 701, Republic of Korea
Biotechnol Appl Biochem 52:283-91. 2009..The present study provides a useful strategy for enhancing the sialylation of therapeutic glycoproteins produced in CHO cells...
- Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta-analysisMaria G Garcia
The National Institute of Perinatology, Mexico City, Mexico
J Perinatol 22:108-11. 2002Using the approach of a meta-analysis, we sought to determine whether the administration of recombinant erythropoietin (rEpo) to very low birth weight (VLBW) infants, after the first week of life, results in fewer "late" ..
- Recombinant human erythropoietin in preoperative autologous blood donation did not influence the haemoglobin recovery after surgeryA Avall
Department of Anesthesia and Intensive Care, East Hospital, Goteborg, Sweden
Acta Anaesthesiol Scand 47:687-92. 2003..The aim of the study was to determine endogenous erythropoietin production and haemoglobin recovery after preoperative autologous blood donation and surgery, with or without recombinant human erythropoietin treatment...
- Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurityMark S Brown
Department of Pediatrics, Presbyterian St Luke s Medical Center, and Department of Preventive Medicine and Biometrics, University of Colorado School of Medicine, Denver, Colorado 80218, USA
J AAPOS 10:143-9. 2006..in a regional referral hospital changed substantially during 1995 to 1998 and presented us with an opportunity to examine whether there was a protective effect on risk of retinopathy associated with exposure to recombinant erythropoietin.
- Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivoD Ribatti
Institute of Human Anatomy, Histology and Embryology, Department of Biomedical Sciences and Human Oncology, University of Bari School of Medicine, Bari, Italy
Blood 93:2627-36. 1999..Taken together, these data demonstrate the ability of Epo to interact directly with endothelial cells and to elicit an angiogenic response in vitro and in vivo and thus act as a bona fide direct angiogenic factor...
- Iron deficiency and erythropoiesis: new diagnostic approachesCarlo Brugnara
Children s Hospital Boston, Department of Laboratory Medicine, 300 Longwood Ave, Boston, MA 02115, USA
Clin Chem 49:1573-8. 2003..The combination of hematologic markers such as reticulocyte hemoglobin content, which decreases with iron deficiency, and R/F ratio may allow for a more precise classification of anemias...
- Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in ratsLei Wang
Department of Neurology, Henry Ford Health Sciences Center, Detroit, Mich, USA
Stroke 35:1732-7. 2004..Erythropoietin (EPO) promotes proliferation and differentiation of erythroid progenitors and the survival of maturing erythroid cells. Here, we investigated the role of EPO in brain repair after stroke...
- Molecular biology of erythropoietinWolfgang Jelkmann
Institute of Physiology, University of Luebeck, Luebeck, Germany
Intern Med 43:649-59. 2004..Whether the recent demonstration of EPO receptors in various non-hemopoietic tissues, including tumor cells, is welcome or ominous still needs to be clarified. Evidence suggests that rHuEPO may be a useful neuroprotective agent...
- Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasmAnantha Vijay R Santhanam
Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Stroke 36:2731-7. 2005..study, the effect of subarachnoid hemorrhage (SAH) on the phosphorylation of endothelial NO synthase (eNOS) and the ability of recombinant erythropoietin (Epo) to augment this vasodilator mechanism in the spastic arteries were studied.
- Erythropoietin both protects from and reverses experimental diabetic neuropathyRoberto Bianchi
Mario Negri Institute of Pharmacological Research, 20157 Milan, Italy
Proc Natl Acad Sci U S A 101:823-8. 2004..These observations suggest that administration of rhEPO or its analogues may be useful in the treatment of diabetic neuropathy...
- Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma modelsKenneth R LaMontagne
Drug Discovery, Growth Factors, Johnson and Johnson Pharmaceutical Research and Development, Room B354, OMP Building, 1000 Route 202, PO Box 300, Raritan, NJ 08869, USA
Mol Cancer Ther 5:347-55. 2006..These results show that recombinant epoetins do not evoke a physiologic response on EPOR-bearing tumor cells as assessed by numerous variables, including growth, migration, and cytotoxic challenge in preclinical in vivo tumor models...
- Erythropoietin and renoprotectionFerdinand H Bahlmann
Department of Internal Medicine IV, Saarland University Medical Centre, Homburg Saar, Germany
Curr Opin Nephrol Hypertens 18:15-20. 2009..Finally, we will review the current literature on clinical studies with rHuEPO or analogous substances and progression of chronic kidney disease, and propose possible clinical renoprotective strategies...
- Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patientsJulia Bohlius
Department of Internal Medicine I, University of Cologne, Germany
J Natl Cancer Inst 98:708-14. 2006..08, 95% CI = 0.99 to 1.18; 42 trials and 8167 patients). Caution is advised when using epoetin or darbepoetin in combination with thrombogenic chemotherapeutic agents or for cancer patients who are at high risk for thrombo-embolic events...
- September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agentsMatti S Aapro
Multidisciplinary Oncology Institute, Genolier, Switzerland
Oncologist 13:33-6. 2008..A sustained hemoglobin level of about 12 g/dl should be the target for treatment with ESAs. ESAs should be used according to the EORTC guidelines and within label with carefully considered exceptions...
- Long-acting EPO analog for treating anemia associated with chronic kidney diseaseGEORGE NORBERT COX; Fiscal Year: 2010..PUBLIC HEALTH RELEVANCE: Recombinant erythropoietin (EPO) is widely used to ameliorate anemia in patients with chronic kidney disease, which affects 20- 40 ..
- Brain imaging and developmental follow-up of infants treated with erythropoietinRobin K Ohls; Fiscal Year: 2013..One promising intervention is the use of recombinant erythropoietin (Epo, also known as an erythropoiesis stimulating agent, or ESA)...
- Preterm Epo Neuroprotection Trial (PENUT Trial) CCCSandra E Juul; Fiscal Year: 2013..New approaches are needed to improve these outcomes. Recombinant erythropoietin (Epo) is a promising novel neuroprotective agent...
- Preterm Epo Neuroprotection Trial (PENUT Trial) DCCPatrick J Heagerty; Fiscal Year: 2013..New approaches are needed to improve these outcomes. Recombinant erythropoietin (Epo) is a promising novel neuroprotective agent...
- BMP4 dependent stress erythropoiesis pathway in short-term radioprotectionROBERT FRANK PAULSON; Fiscal Year: 2013..work, however, suggests that the primary therapies for anemia, transfusion therapy and treatment with recombinant erythropoietin (Epo), can themselves cause pathology...
- Phosphatase Targets of Lenalidomide in Myelodysplastic SyndromeAlan F List; Fiscal Year: 2012..therapeutic challenge in MDS with only a minority of patients experiencing sustained benefit from recombinant erythropoietin (EPO)...
- RADIOASSAY OF ERYTHROPOIETINGISELA CLEMONS; Fiscal Year: 1991..These studies may be of future clinical value in treatment of the anemia in premature infants with recombinant erythropoietin. Other animal studies are concerned with the effect of other hormones on renal erythropoietin synthesis ..
- Epo Neuroprotection of ELBW Infants: Planning GrantSandra E Juul; Fiscal Year: 2010..a detailed research plan in order to carry out a multicenter randomized controlled trial of high dose recombinant erythropoietin (rEpo) as an early intervention to improve long-term neurological outcomes in extremely low birth weight ..
- A NOVEL ELECTROPORATION SYSTEM FOR GENE THERAPY WITH EPOMAIDA DE LAS ALAS; Fiscal Year: 2002..Anemia is currently treated with repeated administration of recombinant erythropoietin (EPO), which is expensive and not readily available to these patients due to the already elevated cost ..
- CLINICAL MODEL OF ERYTHROPOIETIN GENE THERAPYWilliam Osborne; Fiscal Year: 1999..In the USA the estimated annual cost of recombinant erythropoietin for the 85,000 patients with anemia of chronic renal failure is about $500 million...
- Epo as a Rescue Agent for Perinatal Hypoxia-IschemiaSandra Juul; Fiscal Year: 2004....
- Nonhematopoietic Developmental Functions of EPOSandra Juul; Fiscal Year: 2004..We feel these experiments will provide important specific insights into the regulation of neonatal intestinal growth and injury. ..
- Antiestrogenic Effects on Tumor AngiogenesisKimberly Blackwell; Fiscal Year: 2006..The results of this project will have profound implications, especially as clinicians begin to use the newer estrogen receptor modulating drugs for the prevention and treatment of breast cancer. ..
- Anti-Inflammatory and Anti-Oxidative Nutrition in Dialysis PatientsKamyar Kalantar Zadeh; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Nutritional/Inflammatory Evaluation of Dialysis PatientsKamyar Kalantar Zadeh; Fiscal Year: 2005....
- Inner-City NephrologyOnyekachi Ifudu; Fiscal Year: 2002..abstract_text> ..
- Erythropoietin receptors in breast cancerMURAT ARCASOY; Fiscal Year: 2008..abstract_text> ..
- 2006 Cancer Model MechanismsWilliam Kaelin; Fiscal Year: 2006..unreadable] [unreadable] [unreadable] [unreadable]..
- Erythropoiesis & pulse arginine butyrate in sickle cellSusan Perrine; Fiscal Year: 2005..Abstract Not Provided ..
- Physician Training Program in Neonatal BiologyJohn Widness; Fiscal Year: 2007..With NIH support beyond that which the investigators currently enjoy, the investigators will be able to significantly enhance the research training experiences they offer their postdoctoral physician trainees in neonatal medicine. ..
- Best Practices in Transfusion Medicine for Patients with Sickle Cell DiseaseTheodore Wun; Fiscal Year: 2007..Use of these pathways will improve the care for these patients. (End of Abstract) [unreadable] [unreadable] [unreadable]..
- Temporal lobe epilepsy - validation of a new animal modelTore Eid; Fiscal Year: 2008..More effective therapies of epilepsy are therfore needed. This proposal seeks to validate a new animal model that may greatly speed up the search for better therapies against this disorder. ..
- Impact of Medicaid Policy on cardiovascular drug use and clinical outcomesMichael A Fischer; Fiscal Year: 2010....
- PULMONARY ENDOTHELIAL FUNCTION DURING CHRONIC HYPOXIABenjimen Walker; Fiscal Year: 2008..unreadable] [unreadable]..
- A Luciferase Fusion Protein Library to Identify & Monitor Ubiquitylation TargetsWilliam Kaelin; Fiscal Year: 2008..Reisolation of HIF in aims 2 and 3 would constitute proof of concept with respect to the potential utility of this approach. ..
- TREATMENT OF TRAUMATIC BRAIN INJURY WITH SIMVASTATINAsim Mahmood; Fiscal Year: 2009..abstract_text> ..
- TRAUMATIC BRAIN INJURY AND MARROW STROMAL CELLSAsim Mahmood; Fiscal Year: 2009..If the treatment combining MSCs with simvastatin is found to be more effective than monotherapy, this will increase the clinical relevance of MSC treatment by allowing us to use smaller and safer doses. ..
- Mechanisms of adhesion and growth control in stem cellsReuben Kapur; Fiscal Year: 2008..Our proposed studies will provide unique insights into the physiologic significance of the in vivo interactions between class IA PI3K, PTEN and ROCK1 in regulating growth and survival in SC/Ps. ..
- Oral Therapeutic for Beta-ThalassemiaSusan Perrine; Fiscal Year: 2006..unreadable] [unreadable]..
- Evaluation of the Quality of Clinical TrialsBenjamin Djulbegovic; Fiscal Year: 2006..It is also hoped that public confidence in COG research may further increase, which in turn will enable development of more rapid advances in the war against cancer. ..
- Real-Time Imaging of Hypoxia based on VHL ActivityWilliam Kaelin; Fiscal Year: 2006..unreadable] [unreadable]..
- CANCER AND LEUKEMIA GROUP BMARGARET KESSINGER; Fiscal Year: 2002..During the coming grant period, UNMC will continue to make major contributions to group accrual, group science and group administration. Additional financial support will facilitate and strengthen these contributions. ..
- Mechanisms of adhesion and growth control in stem cellsReuben Kapur; Fiscal Year: 2010..Our proposed studies will provide unique insights into the physiologic significance of the in vivo interactions between class IA PI3K and phosphatases in regulating growth and survival in SC/Ps. ..
- FETAL GLOBIN INDUCTION IN BETA THALASSEMIASusan Perrine; Fiscal Year: 2002..These studies should determine the proportion and some genotypes of beta thalassemia patients which can benefit from Pulsed Butyrate plus/minus rhu-EP0 therapy. ..
- NCI TRANSITION CAREER DEVELOPMENT AWARDTheresa Gillespie; Fiscal Year: 2003....
- A QTL for fetal hemoglobin and F cells on chromosome 8qSwee Thein; Fiscal Year: 2003..The discovery of these factors may also suggest new approaches for therapeutic augmentation of fetal hemoglobin production in patients with SCD and beta thalassemia. ..
- Equipoise and the research integrity of clinical trialsBenjamin Djulbegovic; Fiscal Year: 2003..This proposal will answer both the question "what do trials do for us?" and assess the reliability of the research in which public has invested so much. ..
- Postoperative Cognitive Dysfunction in the ElderlyTerri Monk; Fiscal Year: 2004..Given the breadth of my proposed training program, I will be able to interact with and serve as a mentor for anesthesiologists and also the broader corpus of scientists, both clinical and basic, interested in aging and neuroscience. ..
- Vascular Role of Carbon Monoxide during Chronic HypoxiaBenjimen Walker; Fiscal Year: 2004..The proposed experiments utilize a variety of in vivo and in vitro approaches to examine questions central to the regulation of the systemic circulation by a novel vasodilatory pathway under clinically relevant conditions. ..
- NO AND EXERCISE VASODILATION IN HUMAN HYPERLIPIDEMIAMichael Joyner; Fiscal Year: 2004..Data from these patient- oriented studies have implications related to understanding the contribution of endothelial function in a variety of common diseases. ..
- Herpes Simplex Virus, Early Brain Injury and EpilepsyTore Eid; Fiscal Year: 2004..If a viral causation of TLE is established, then this would not only open new avenues for prevention and control of this disorder, but also improve our understanding of viral-induced brain injury. ..
- Epo-dependent JAK2 Signaling in Painful NeuropathyWENDY CAMPANA; Fiscal Year: 2006..The experiments will provide new information on the basic mechanisms of nerve injury and pain, and there from, new rationale for development of novel neuroprotective strategies for preventing chronic neuropathic pain. ..
- MECHANISMS OF HYPOALBUMINEMIA IN ENDSTAGE RENAL DISEASEGeorge Kaysen; Fiscal Year: 2001..We will further establish the effect of KT/V, dialyzer permeability and reuse on changes in albumin, nutritional status and acute phase response. ..
- Using Synthetic Lethality to Select Cancer Drug TargetsWilliam Kaelin; Fiscal Year: 2005..Moreover, they may establish a new paradigm for the selection of anticancer drug targets based on inactivating mutations of TSG. ..
- MECHANISM OF RETINAL ISCHEMIADANIEL ROSENBAUM; Fiscal Year: 2005..b) Multi-modal therapy employing caspase inhibitor(s) and anti-excitotoxic strategies work synergistically toreduce ischemic retinal damage. ..
- Pharmacophore-Modeled Screening for HbF-Inducing AgentsSusan Perrine; Fiscal Year: 2004..virtual screening using molecular modeling with confirmation by reporter assay and selection of a specific HDAC activity should generate additional compounds for development of an optimal HbF inducer for an effective life-long treatment ..
- 2008 AUA/SBUR Summer Research ConferenceArthur Burnett; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Osteoporosis Prevention in Early Stage Breast CancerDawn Hershman; Fiscal Year: 2006..abstract_text> ..
- NITRIC OXIDE REGULATORY SYSTEM IN THE PENISArthur Burnett; Fiscal Year: 2002....
- Simvastatin treatment of experimental intracerebral hemorrhageDONALD M SEYFRIED; Fiscal Year: 2010....
- Proteomic Analysis of Retinal Ganglion Cell Death in GlaucomaGULGUN TEZEL; Fiscal Year: 2010..These studies are expected to provide comprehensive information about the nerve cell death process, thereby allowing new treatment possibilities for 3 million Americans suffering from glaucoma. ..
- CENTER FOR STROKE RESEARCHMichael Chopp; Fiscal Year: 2007..Our studies are designed to improve neurological function and the management of the stroke patient. ..
- Treatment of Neural Injury with MSCsMichael Chopp; Fiscal Year: 2007..The long-term goal of this Program Project application is to translate our finding of therapeutic benefit after treatment of experimental stroke and traumatic brain injury with MSCs to the patient. ..
- ANTIICAM-1 AND RTPA TREATMENT OF EMBOLIC STROKEMichael Chopp; Fiscal Year: 2002..This technology and the proposed experiments will enhance our understanding of the mechanisms underlying microvascular dysfunction and occlusion after stroke and thrombolytic treatment. ..
- Estrogen and the Aging Blood Brain BarrierOAK CHI; Fiscal Year: 2002..The information obtained from our study will be crucially important for the clinical application of estrogen therapy for stroke as well as understanding the pathophysiology of age related cerebrovascular changes. ..
- Intervention for Colorectal CancerCharles Bennett; Fiscal Year: 2003..The proposed interventions will improve the standard Veterans Affairs colorectal cancer screening protocol and will provide a model for methods and materials to increase screening rates in other settings. ..